

MARKET REPORT



Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

Summary

Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question. This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza. The global viral infections market was valued at \$74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching \$117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.

Scope

The viral infections market is large and growing rapidly

- How do epidemiology trends differ among the key indications?
- What therapeutic options exist for preventing and treating viral infections?
- Which products and companies dominate the market?

The pipeline is innovative and diverse

- What is the proportion of early- to late-stage pipeline products?
- Which molecular targets are most prominent within the pipeline?
- How do the key indications differ in terms of molecule type?

Considerable market growth is anticipated throughout 2021

- Which products will contribute to this growth most significantly?
- Will the current market leaders retain their dominance over the forecast period?

Deal values for licensing and co-development deals range considerably

- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?

Reasons to buy

This report will allow you to -

- Examine the current clinical and commercial landscape by considering disease pathogenesis, treatment options and key marketed products.
- Appreciate how the four key indications - HIV, HCV, HBV and influenza - differ in terms of epidemiology, symptoms and co-morbidities and complications.
- Identify trends and developments, in terms of molecule type and molecular target, within the overall viral infections pipeline, as well as for each of the four key indications.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
- Recognize how the evolving treatment landscape will drive market growth to 2021 and understand the contributions that different products, molecular targets and companies will make to this growth.
- Understand how strategic consolidations have shaped the current pipeline and marketed product landscapes.

Additional Details

Publisher : GBI Research

Reference :

Number of Pages : 179

Report Format : PDF

Publisher Information :

GBI RESEARCH
GLOBAL BUSINESS INTELLIGENCE

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

- 1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 62 Introduction 92.1 Therapy Area Introduction 92.2 Human Immunodeficiency Virus (HIV) 92.2.1 Overview 92.2.2 Symptoms 102.2.3 Co-morbidities and Complications 102.2.4 Epidemiology 112.3 Hepatitis C Virus 122.3.1 Overview 122.3.2 Symptoms 132.3.3 Co-morbidities and Complications 132.3.4 Epidemiology 142.4 Hepatitis B Virus 142.4.1 Overview 142.4.2 Symptoms 152.4.3 Co-morbidities and Complications 152.4.4 Epidemiology 162.5 Influenza 162.5.1 Overview 162.5.2 Symptoms 172.5.3 Co-morbidities and Complications 172.5.4 Epidemiology 172.6 Etiology and Pathogenesis of Viral Infections 182.7 Treatment for Viral Infections 192.7.1 Vaccines 192.7.2 Antiviral Agents 203 Marketed Products 223.1 Multiple Indications 223.1.1 Viread - Gilead 223.1.2 Epivir/Epivir-HBV - ViiV Healthcare 233.1.3 Pegasys - F. Hoffmann La Roche 253.2 Human Immunodeficiency Virus (HIV) 263.2.1 Truvada - Gilead 263.2.2 Atripla - Gilead 283.2.3 Stribild - Gilead 293.2.4 Tivicay - ViiV Healthcare 313.2.5 Triumeq - ViiV Healthcare 323.2.6 Genvoya - Gilead 333.3 Hepatitis C Virus (HCV) 353.3.1 Olysio - Janssen 353.3.2 Sovaldi and Harvoni - Gilead 363.3.3 Zepatier - Merck and Co. 383.4 Hepatitis B Virus 393.4.1 Baraclude - Bristol-Myers Squibb 393.5 Influenza Virus 403.5.1 Tamiflu - Roche 404 Pipeline 424.1 Overview 424.2 Pipeline Products by Stage of Development and Molecule Type 424.3 Pipeline Products by Molecular Target 474.4 Clinical Trials Landscape 504.4.1 Clinical Trial Failure Rates 514.4.2 Clinical Trial Duration 544.4.3 Clinical Trial Size 574.4.4 Cumulative Clinical Trial Size 614.4.5 Conclusion 634.5 Assessment of Key Pipeline Products 634.5.1 Sofosbuvir in Combination with Velpatasvir - Gilead 634.5.2 Tenofovir alafenamide fumarate - Gilead 654.5.3 Descovy - Gilead 664.5.4 Cobicistat, darunavir, emtricitabine and TAF - Johnson & Johnson 674.5.5 Beclabuvir hydrochloride - Bristol-Myers Squibb 684.5.6 V-212 - Merck 695 Multi-scenario Market Forecast to 2021 715.1 Revenues Analysis by Molecular Target 735.1.1 Reverse Transcriptase 735.1.2 Nonstructural Protein 5B Polymerase and Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A 745.1.3 HIV Integrase 755.1.4 Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase 765.1.5 NS3-4A Protease/Nonstructural Protein 5A 775.2 Revenue and Market Share Analysis by Company 785.2.1 Gilead Sciences - Monopolization of Market to Continue Throughout 2021 815.2.2 Merck - Uptake of Zepatier and Gardasil 9 to Encourage Strong Growth 825.2.3 GlaxoSmithKline - Tivicay and Triumeq to Propel Company Revenues 835.2.4 Johnson and Johnson - Market Share to Dwindle as Sales for Prezista and Olysio Decline 855.2.5 Bristol-Myers Squibb - Marginalization Due to Patent Expirations 866 Company Analysis and Positioning 876.1 Company Landscape 877 Strategic Consolidations 907.1 Licensing Deals 907.1.1 Deals by Region, Value, Year and Indication 907.1.2 Deals by Stage of Development and Value 927.1.3 Deals by Molecule Type, Molecular Target and Value 937.2 Co-development Deals 987.2.1 Deals by Region, Value, Year and Indication 987.2.2 Deals by Stage of Development and Value 1007.2.3 Deals by Molecule Type, Molecular Target and Value 1018 Appendix 1048.1 References 1048.2 Abbreviations 1128.3 Table of All Pipeline Products 1138.4 Methodology 1778.4.1 Coverage 1778.4.2 Secondary Research 1778.4.3 Market Size and Revenue Forecasts 1788.4.4 Pipeline Analysis 1788.4.5 Competitive Landscape 1798.5 Contact Us 1798.6 Disclaimer 179

List Of Tables in Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

1.1 List of Tables

Table 1: Common Routes of Viral Entry 18

Table 2: Viral Infections Therapeutics Market, Global, Licensing Deals Valued Above \$100m, 2006-2016 95

Table 3: Viral Infections Therapeutics Market, Global, Co-development Deals Valued Above \$100m, 2006-2016 103

Table 4: Table of All Pipeline Products 113

List Of Figures, Charts and Diagrams in Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

1.2 List of Figures

Figure 1: Viral Infections Therapeutics Market, Major Markets, HIV Prevalence ('000), 2014-2021 12

Figure 2: Viral Infections Therapeutics Market, Major Markets, HCV Prevalence ('000), 2014-2021 14

Figure 3: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Viread (\$m), 2006-2021 23

Figure 4: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Epivir/Epivir-HBV (\$m), 2006-2021 24

Figure 5: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Pegasys (\$m), 2006-2021 26

Figure 6: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Truvada (\$bn), 2006-2021 28

Figure 7: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Atripla (\$bn), 2006-2021 29

Figure 8: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Stribild (\$bn), 2012-2021 30

Figure 9: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tivicay (\$bn), 2013-2021 31

Figure 10: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Triumeq (\$bn), 2015-2021 33

Figure 11: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Genvoya (\$bn), 2016-2021 34

Figure 12: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Olysio (\$m), 2013-2021 36

Figure 13: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Sovaldi and Harvoni (\$bn), 2013-2021 37

Figure 14: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Zepatier (\$bn), 2016-2021 38

Figure 15: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Baraclude (\$m), 2006-2021 40

Figure 16: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tamiflu (\$m), 2006-2021 41

Figure 17: Overall Pharmaceutical Industry Pipeline by Therapy Area, Global, 2016 42

Figure 18: Viral Infections Therapeutics Market, Global, Pipeline for Viral Infections by Stage of Development and <https://www.bioportfolio.co.uk/product/25771>
reportstore@bioportfolio.com to order

Molecule Type, 2016 43

Figure 19: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2016 45

Figure 20: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2016 46

Figure 21: Viral Infections Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 48

Figure 22: Viral Infections Therapeutics Market, Global, Breakdown of Viral Surface Protein, Immune Mediator and Polymerase Molecular Targets, 2016 49

Figure 23: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2016 50

Figure 24: Viral Infections Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006-2016 51

Figure 25: Viral Infections Therapeutics Market, Global, Clinical Trial Failure and Attrition Rates by Indication and Stage of Development (%), 2006-2016 52

Figure 26: Viral infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 53

Figure 27: Viral Infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 54

Figure 28: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Indication and Stage of Development (Months), 2006-2016 55

Figure 29: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (Months), 2006-2016 56

Figure 30: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (Months), 2006-2016 57

Figure 31: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Indication and Stage of Development (Participants), 2006-2016 58

Figure 32: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016 59

Figure 33: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016 60

Figure 34: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Indication and Stage of Development (participants), 2006-2016 61

Figure 35: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016 62

Figure 36: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016 63

Figure 37: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Sofosbuvir in Combination with Velpatasvir (\$bn), 2016-2021 65

Figure 38: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for TAF (\$bn), 2016-2021 66

Figure 39: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Descovy (\$bn), 2016-2021

Figure 40: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Cobicistat in combination with darunavir, emtricitabine and TAF (\$bn), 2016-2021 68

Figure 41: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Beclabuvir Hydrochloride (\$bn), 2016-2021 69

Figure 42: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for V-212 (\$m), 2017-2021 70

Figure 43: Viral Infections Therapeutics Market, Global, Market Size (\$bn), 2014-2021 71

Figure 44: Viral Infections Therapeutics Market, Global, Forecast Revenues for Strongest Commercial Products, 2014-2021 72

Figure 45: Viral Infections Therapeutics Market, Global, Premium and Generic Market Share (\$bn), 2014-2021 73

Figure 46: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Reverse Transcriptase (\$bn), 2014-2021 74

Figure 47: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A, (\$bn), 2014-2021 75

Figure 48: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting HIV Integrase, (\$bn), 2014-2021 76

Figure 49: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase, (\$bn), 2014-2021 77

Figure 50: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting NS3-4A Protease/Nonstructural Protein 5A, (\$bn), 2014-2021 78

Figure 51: Viral Infections Therapeutics Market, Global, Revenues by Company, 2014-2021 78

Figure 52: Viral Infections Therapeutics Market, Global, Companies by Compound Annual Growth Rate (CAGR), 2014-2021 79

Figure 53: Viral Infections Therapeutics Market, Global, Companies by Market Share, 2014-2021 79

Figure 54: Viral Infections Therapeutics Market, Revenues by Route of Acquisition, 2014-2021 80

Figure 55: Viral Infections Therapeutics Market, Gilead Sciences Annual Revenues (\$bn), 2014-2021 81

Figure 56: Viral Infections Therapeutics Market, Global, Gilead Sciences Annual Revenues by Product (\$m), 2014-2021 82

Figure 57: Viral Infections Therapeutics Market, Merck Annual Revenues (\$bn), 2014-2021 83

Figure 58: Viral Infections Therapeutics Market, Global, Merck Annual Revenues by Product (\$m), 2014-2021 83

Figure 59: Viral Infections Therapeutics Market, GlaxoSmithKline Annual Revenues (\$bn), 2014-2021 84

Figure 60: Viral Infections Therapeutics Market, Global, GlaxoSmithKline Annual Revenues by Product (\$m), 2014-2021 84

Figure 61: Viral Infections Therapeutics Market, Johnson and Johnson Annual Revenues (\$bn), 2014-2021 85

Figure 62: Viral Infections Therapeutics Market, Global, Johnson and Johnson Annual Revenues by Product (\$m), 2014-2021 85

Figure 63: Viral Infections Therapeutics Market, Bristol-Myers Squibb Annual Revenues (\$bn), 2014-2021 86

Figure 64: Viral Infections Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenues by Product (\$m), 2014-2021 86

Figure 65: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016 87

Figure 66: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016 88

Figure 67: Viral Infections Therapeutic Market, Global, Proportion of Total Company Revenue Attributed to Viral Infection Products, 2014-2021 89

Figure 68: Viral Infections Therapeutics Market, Global, Licensing Deals by Region, Deal Value and Year, 2006-2016 91

Figure 69: Viral Infections Therapeutics Market, Global, Licensing Deals by Indication and Deal Value, 2006-2016 92

Figure 70: Viral Infections Therapeutics Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016 93

Figure 71: Viral Infections Therapeutics Market, Global, Licensing Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016 94

Figure 72: Viral Infections Therapeutics Market, Global, Co-development Deals by Region, Deal Value and Year, 2006-2016 99

Figure 73: Viral Infections Therapeutics Market, Global, Co-development Deals by Indication and Deal Value, 2006-2016 100

Figure 74: Viral Infections Therapeutics Market, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016 101

Figure 75: Viral Infections Therapeutics Market, Global, Co-development Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016 102

How to Buy...

Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/25771>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$4995** | Single User Price
- \$9990** | Site License Price
- \$14985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.